207 related articles for article (PubMed ID: 31323705)
1. Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection.
Usman Z; Mijočević H; Karimzadeh H; Däumer M; Al-Mathab M; Bazinet M; Frishman D; Vaillant A; Roggendorf M
J Viral Hepat; 2019 Dec; 26(12):1454-1464. PubMed ID: 31323705
[TBL] [Abstract][Full Text] [Related]
2. Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.
Mijočević H; Karimzadeh H; Seebach J; Usman Z; Al-Mahtab M; Bazinet M; Vaillant A; Roggendorf M
J Viral Hepat; 2019 Apr; 26(4):485-495. PubMed ID: 30450662
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
4. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
[TBL] [Abstract][Full Text] [Related]
5. Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients.
Yang J; Yang G; He H; Ning L; Liu Z; Fu Q; Chen H; Deng H; Wang Z; Luo K
Antivir Ther; 2018; 23(7):567-574. PubMed ID: 30095435
[TBL] [Abstract][Full Text] [Related]
6. Early changes in quasispecies variant after antiviral therapy for chronic hepatitis B.
Liang Y; Yano Y; Putri WA; Mardian Y; Okada R; Tanahashi T; Murakami Y; Hayashi Y
Mol Med Rep; 2018 Apr; 17(4):5528-5537. PubMed ID: 29393485
[TBL] [Abstract][Full Text] [Related]
7. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
8. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing.
Wang Y; Xiao X; Chen S; Huang C; Zhou J; Dai E; Li Y; Liu L; Huang X; Gao Z; Wu C; Fang M; Gao C
Front Immunol; 2021; 12():775461. PubMed ID: 34899733
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection.
Al-Mahtab M; Bazinet M; Vaillant A
PLoS One; 2016; 11(6):e0156667. PubMed ID: 27257978
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
11. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
12. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2022 Aug; 6(8):1870-1880. PubMed ID: 35368148
[TBL] [Abstract][Full Text] [Related]
13. Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy.
Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
Hepatol Commun; 2021 Nov; 5(11):1873-1887. PubMed ID: 34558823
[TBL] [Abstract][Full Text] [Related]
14. Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay.
Gencay M; Vermeulen M; Neofytos D; Westergaard G; Pabinger S; Kriegner A; Seffner A; Gohl P; Huebner K; Nauck M; Kaminski WE
J Clin Virol; 2018 Apr; 101():38-43. PubMed ID: 29414186
[TBL] [Abstract][Full Text] [Related]
15. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
16. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
17. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.
Boyd A; Canini L; Gozlan J; Lascoux-Combe C; Miailhes P; Fonquernie L; Girard PM; Lacombe K
J Clin Virol; 2017 Oct; 95():55-60. PubMed ID: 28869890
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
[TBL] [Abstract][Full Text] [Related]
19. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
[TBL] [Abstract][Full Text] [Related]
20. Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.
Velay A; Jeulin H; Eschlimann M; Malvé B; Goehringer F; Bensenane M; Frippiat JP; Abraham P; Ismail AM; Murray JM; Combet C; Zoulim F; Bronowicki JP; Schvoerer E
J Viral Hepat; 2016 May; 23(5):387-98. PubMed ID: 26742490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
